Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
Leading Canadian researcher calls for inclusion of co-infected people in large HCV clinical trials

Stephen Shafran from the University of Alberta performed a major review of clinical trials of many DAA-containing HCV therapies used for the treatment of HCV mono-infection as well as HIV-HCV co-infection. Cure rates of HCV are “remarkably similar” in HCV mono-infected and co-infected participants who were treated with the same regimen and who have the same strain (genotype) of HCV.

Published
3 hours ago
From
CATIE
The Medicines Patent Pool Releases Independent Feasibility Studies on Hepatitis C and Tuberculosis

As part of its ongoing consultation processes on the possibility of the Medicines Patent Pool (MPP) expanding into other disease areas, the organisation has published independent feasibility studies exploring the case for potential entry into Hepatitis C and Tuberculosis.

Published
5 hours ago
From
Medicines Patent Pool
People with HIV and HCV co-infection who have fibrosis stages F2 and above should be prioritised for new anti-HCV therapies

People with HIV and hepatitis C virus (HCV) co-infection who have advanced liver fibrosis should be prioritised for therapy with new anti-HCV drugs, investigators argue in AIDS.

Published
02 July 2015
By
Michael Carter
FDA is Sued by Advocacy Groups That Want Gilead Hepatitis C Trial Data

Specifically, the groups hope to learn about different responses that different patients experienced during clinical trials. Tracy Swan of Treatment Action Group points to relapses in a Harvoni clinical trial that occurred only among African-Americans. The groups also want to perform an independent analysis of poor prognostic factors among people who were not cured in order to identify a patient profile.

Published
29 June 2015
From
Wall Street Journal (blog)
AbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C Patients with Compensated Liver Cirrhosis

AbbVie, a global biopharmaceutical company, today announced TURQUOISE-III study results demonstrating 100 percent (n=60/60) sustained virologic response at 12 weeks post-treatment (SVR12) in genotype 1b (GT1b) chronic hepatitis C virus (HCV) infected adult patients with compensated liver cirrhosis. These new results from AbbVie's Phase 3b study will be presented at the 15th Annual International Symposium on Viral Hepatitis and Liver Diseases in Berlin, Germany.

Published
24 June 2015
From
AbbVie press release
Sofosbuvir plus daclatasvir for 12 weeks cures HCV for most people with HIV/HCV co-infection

Nearly all trial participants with HIV and hepatitis C virus (HCV) co-infection, who were treated for 12 weeks with an interferon- and ribavirin-free regimen of sofosbuvir

Published
03 June 2015
By
Liz Highleyman
Achillion partners with J&J to develop hepatitis C drugs

Achillion Pharmaceuticals Inc said it will collaborate with Johnson & Johnson to develop and market its hepatitis C drugs including an oral regimen that could work on all genotypes and shorten treatment time.

Published
20 May 2015
From
Reuters
Gilead triple combination cures easy-to-treat hepatitis C patients in 6 weeks, but 4 weeks is not enough

A six-week regimen of sofosbuvir (Sovaldi) plus two experimental direct-acting antivirals being developed by Gilead Sciences cured more than 90% of previously untreated people with genotype 1 hepatitis

Published
15 May 2015
By
Liz Highleyman
Shortening hepatitis C treatment to 6 weeks effective but not perfect for easier-to-treat patients

Shortening hepatitis C treatment to 6 weeks for easier-to-treat patients without cirrhosis does not greatly reduce the efficacy of hepatitis C treatment for people with genotype 1

Published
15 May 2015
By
Keith Alcorn
Sofosbuvir-based therapy effective for hepatitis C patients with decompensated cirrhosis

Interferon-free regimens containing sofosbuvir (Sovaldi) plus simeprevir (Olysio) cured about three-quarters of people with genotype 1 chronic hepatitis C with advanced cirrhosis and MELD scores >10 in

Published
11 May 2015
By
Liz Highleyman
← First12345...57Next →

Filter by country